Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 4 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Observational 4Interventional 3

Sponsor

Cancer Type

Endocrine 2Lymphoid 1CNS 1

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

candesartan 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × Essential Hypertension × Clear all
NCT01022515 2026-02-06

PHEO

University Hospital, Rouen

Phase NA Completed
60 enrolled
CNSEndocrine

Essential Hypertension, Hypertension, Paraganglioma, Pheochromocytoma

NCT07375407 2026-02-02

Aerobic Exercise vs Physiological Ischemic Training in Stage 2 Hypertension

Universitas Padjadjaran

Phase NA Completed
60 enrolled
Lymphoid

Essential Hypertension, Lymphoma, Follicular

NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡